A phase I trial of BNC105P and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia

EJHaem. 2022 Aug 11;3(4):1445-1448. doi: 10.1002/jha2.543. eCollection 2022 Nov.

Darcy B Pooler^{1

2}, Dylan B Ness^{1

2}, Alexey V Danilov³, Bridget M Labrie¹, Tor D Tosteson^{2

4}, Alan Eastman^{2

5}, Lionel D Lewis^{1

2}, Frederick Lansigan^{1

2}

¹ Sections of Clinical Pharmacology and Hematology Oncology Department of Medicine Geisel School of Medicine at Dartmouth and Dartmouth-Hitchcock Medical Center Lebanon New Hampshire USA.
² The Dartmouth Cancer Center at Dartmouth-Hitchcock Medical Center Lebanon New Hampshire USA.
³ Department of Hematology and Hematopoietic Cell Transplantation City of Hope Comprehensive Cancer Center Duarte California USA.
⁴ Department of Biomedical Data Science Geisel School of Medicine at Dartmouth Hanover New Hampshire USA.
⁵ Department of Molecular and Systems Biology Geisel School of Medicine at Dartmouth Hanover New Hampshire USA.

No abstract available

Grants and funding